Instituto de Ensino, Pesquisa e Inovação, Liga Contra o Câncer, Natal, Brazil.
Faculty of Pharmacy, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, Brazil.
Int J STD AIDS. 2024 Sep;35(10):786-795. doi: 10.1177/09564624241259512. Epub 2024 Jun 21.
Evaluate the clinical features in people with Hodgkin's lymphoma living with HIV (HIV-HL) during the combination ART (cART) era.
Systematic review and meta-analysis.
The study was conducted in accordance with the recommendations of 2020 PRISMA and MOOSE statements. The protocol was prospectively registered through the PROSPERO (CRD42021289520). Manuscripts published until July 2023 were systematically searched in the PubMed, EMBASE, Cochrane Library, and Web of Science databases, with no language and year of publication restriction. Meta-analysis was performed to estimate a pooled proportion of each outcome using a random-effect analysis. Quality assessment was performed by using New-Castle Ottawa scale. Certainty of evidence was graded using the GRADE.
Sixteen cohorts, representing 3.882 HIV-HL patients, were included in this review. Our findings indicate that HIV-HL patients showed a 2-year overall survival (OS) of 92% (95% CI 0.87, 0.95). However, the 5-year overall survival decreased to 79% (95% CI 0.74, 0.83), with a high certainty of evidence according to GRADE. Additionally, the 5-year progression-free survival declined to 79% and complete remission rate increased to 81%. Our meta-analysis indicates an increase for B symptoms (80%, 95% CI 0.75, 0.84) and extranodal involvement in bone marrow (43%, 95% CI 0.30, 0.47) among HIV-HL patients.
The HIV-HL patients showed a 2-year OS of 92%. However, the 5-year OS decreased to 79%. The reported main cause of mortality among HIV-HL patients was progression of HL. Our systematic review and meta-analysis suggest that cART is associated with improved short-term survival of HIV-HL patients.
评估在联合抗逆转录病毒疗法（cART）时代患有艾滋病毒（HIV）相关霍奇金淋巴瘤（HIV-HL）患者的临床特征。
系统评价和荟萃分析。
本研究按照 2020 年 PRISMA 和 MOOSE 声明的建议进行。该方案通过 PROSPERO（CRD42021289520）前瞻性注册。系统检索了截至 2023 年 7 月在 PubMed、EMBASE、Cochrane 图书馆和 Web of Science 数据库中发表的手稿，无语言和出版年限限制。使用随机效应分析估算每个结局的合并比例进行荟萃分析。使用纽卡斯尔-渥太华量表进行质量评估。使用 GRADE 对证据确定性进行分级。
本综述纳入了 16 项队列研究，共 3882 例 HIV-HL 患者。我们的研究结果表明，HIV-HL 患者的 2 年总生存率（OS）为 92%（95%CI 0.87，0.95）。然而，5 年总生存率下降至 79%（95%CI 0.74，0.83），根据 GRADE，证据确定性较高。此外，5 年无进展生存率下降至 79%，完全缓解率上升至 81%。我们的荟萃分析表明，HIV-HL 患者 B 症状（80%，95%CI 0.75，0.84）和骨髓外淋巴结受累（43%，95%CI 0.30，0.47）的发生率增加。
HIV-HL 患者的 2 年 OS 为 92%。然而，5 年 OS 下降至 79%。HIV-HL 患者死亡的主要原因是 HL 进展。本系统评价和荟萃分析表明，cART 与 HIV-HL 患者短期生存改善相关。
